Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)
This special issue of “Metabolism, Clinical and Experimental” is dedicated to nonalcoholic fatty liver disease (NAFLD), a disease closely linked with the insulin resistance (IR) syndrome or metabolic syndrome (MetS) [1] and its related comorbidities, including obesity [2], type 2 diabetes mellitus (T2DM) [3], dyslipi demia [4] and cardiovascular disease [5]. The prevalence of NAFLD has been estimated to be about 25%, being higher in selected populations with genetic predisposition (e.g. Hispanics), or certain metabolic traits (e.g.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Stergios A. Polyzos, Christos S. Mantzoros Source Type: research
More News: Biomedical Science | Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Genetics | Heart | Insulin | Liver | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Urology & Nephrology